Earlier this month, the U.S. Food and Drug Administration proposed food companies use new, front-of-package labels highlighting the levels of fat, salt and added sugar in their products.

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.

The FDA has approved Avtozma® (tocilizumab-anoh), a biosimilar to Actemra®, in both intravenous and subcutaneous formulations.

Zenocutuzumab helps fill an important need for patients with advanced pancreatic cancer and NSCLC with NRG1 gene fusions, said Alison Schram M.D., ...

Candidate genetic variants included in a genetic risk algorithm may not meet standards of reasonable clinical efficacy in identifying opioid use disorder risk, according to a study published in JAMA ...

Prime Medicine, Inc. faces risks in the gene editing sector despite positive developments, caution advised for retail investors. Click for my PRME stock update.